Company: CSTL
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001447362-25-000097
Chunk: 16

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-08-04
Form: 10-Q
Item: Item 1
Chunk 16
---
$86,188 $87,002 $174,176 $159,976 (1)Consists of DecisionDx-Melanoma, DecisionDx-SCC and our Diagnostic Gene Expression Profile offering.(2)Consists of TissueCypher, DecisionDx-UM and IDgenetix. 

13

Table of ContentsCASTLE BIOSCIENCES, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)(UNAUDITED)

We have presented disaggregated net revenues included in our single reportable segment in the table above. The characteristics for each test in our single segment are similar, with each test having a single performance obligation. Our CODM is the single individual responsible for managing our segment and reviews consolidated results and budgets in assessing performance and in allocating resources. See Note 15 for additional information about our reportable segment.Payor ConcentrationWe rely upon reimbursements from third-party government payors (primarily Medicare) and private-payor insurance companies to collect accounts receivable related to sales of our tests.Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances were as follows: Percentage of Revenues Six Months EndedJune 30,Percentage of Accounts Receivable (current) as ofPercentage of Accounts Receivable (noncurrent) as of 20252024June 30, 2025December 31, 2024June 30, 2025December 31, 2024Medicare47 %48 %16 %18 %**Payor A15 %15 %17 %19 %16 %15 %Payor B**26 %20 %10 %12 %*    Less than 10%There were no other third-party payors that individually accounted for more than 10% of our total revenue or accounts receivable for the periods shown in the table above.

4. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options, vesting of RSUs and PSUs or purchases under the ESPP. The treasury stock method is used to calculate the potential dilutive effect of these